IMV Inc. (IMV) and Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) Comparison side by side

We will be comparing the differences between IMV Inc. (NASDAQ:IMV) and Ampio Pharmaceuticals Inc. (NYSEAMERICAN:AMPE) as far as analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IMV Inc. N/A 0.00 N/A -0.34 0.00
Ampio Pharmaceuticals Inc. N/A 0.00 10.67M -0.23 0.00

Demonstrates IMV Inc. and Ampio Pharmaceuticals Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
IMV Inc. 0.00% 0% 0%
Ampio Pharmaceuticals Inc. 0.00% -489.2% 381%

Institutional and Insider Ownership

IMV Inc. and Ampio Pharmaceuticals Inc. has shares held by institutional investors as follows: 22.07% and 23.2%. Insiders held roughly 17.98% of IMV Inc.’s shares. Comparatively, Ampio Pharmaceuticals Inc. has 7% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
IMV Inc. -6.37% 3.92% 8.09% -17.52% 50.94% -1.74%
Ampio Pharmaceuticals Inc. -16.28% -0.37% 1.43% -71.67% -66.29% -86.91%

For the past year IMV Inc. has stronger performance than Ampio Pharmaceuticals Inc.

IMV Inc., a clinical-stage company, together with its subsidiaries, develops products based on its platform and products with a primary focus on T cell activating therapies for cancer. The company's DepoVax platform is a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. It has two T cell activation therapies for cancer through Phase I human clinical trial and is conducting a Phase Ib study with Incyte Corporation for lead cancer therapy; and DPX-Survivac, as a combination therapy for ovarian cancer. The company is also conducting a Phase II study for DPX-Survivac in ovarian and lymphoma. In addition, it is developing DPX-RSV, a vaccine candidate, which has completed a Phase I clinical trial for respiratory syncytial virus, as well as has clinical projects to assess the DepoVax to address malaria and the Zika virus; DPX-E7 an investigational immunotherapy that targets a viral protein in human papillomavirus (HPV) known as E7. The company has research collaborations with companies and research organizations, including Merck, Incyte Corporation, and Leidos Inc, as well as with Zoetis. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is based in Halifax, Canada.

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, which has completed Phase II clinical trials for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.